Long-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy
The decision on whether or not to give chemotherapy after breast cancer surgery is always…
Browsing: MINDACT
MINDACT trial data reveal certain women with luminal breast cancer may be undertreated with tamoxifen alone
Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined…
Associate Professor Guy Hingston on MINDACT: Fewer Australian women will now need chemotherapy for breast cancer
MammaPrint genomic testing represents a new paradigm shift in modern breast cancer management Late last…